BackProstatype Genomics AB (publ) Overview

Prostatype Genomics AB (publ) Common Stock

Latest common stock for PROGEN.ST: $5.9M.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$5.92M
↑ 59.97% YoYΔ $2.22M vs prior year quarter

Peer trimmed avg / median

Loading

Prostatype Genomics AB (publ) Common Stock History

Loading

Prostatype Genomics AB (publ) vs. peers: Common Stock Comparison

Loading

Prostatype Genomics AB (publ) Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Prostatype Genomics AB (publ) (PROGEN.ST) FAQ

Prostatype Genomics AB (publ) posts a common stock of $5.9M as of June 2026. That compares with $3.7M in the prior-year period — up 60.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Prostatype Genomics AB (publ)'s common stock was $3.7M. The latest reading is $5.9M — a 60.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Prostatype Genomics AB (publ)'s financial statement story. At $5.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PROGEN.ST's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Prostatype Genomics AB (publ)'s other metric pages and overview cover the third.